DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Sunday, 28 December 2014

Bryan K. S. Yeung.....Profile

 Bryan Yeung

Bryan K. S. Yeung
Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, Singapore 
Associate Director, Malaria Program at Novartis Institute for Tropical Diseases
 SINGAPORE


Involved in programme for antimalarial shown below

http://newdrugapprovals.org/2014/12/27/nitd609/http://newdrugapprovals.org/2014/12/27/nitd609/

Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria

Bryan K. S. Yeung, et al
 *To whom correspondence should be addressed. Phone: +65 6722 2923. Fax: +65 6722 2918. E-mail: bryan.yeung@novartis.com.

Journal of Medicinal Chemistry, 2010 ,  vol. 53,   14  p. 5155 – 5164
http://pubs.acs.org/toc/jmcmar/53/14



 NIBR LOGO 146x50

 SINGAPORE FLAG

Profile

Bryan K S Yeung - ResearchGate

www.researchgate.net/profile/Bryan_Yeung
Researcher » Bryan K S Yeung, Novartis, Novartis Institute for Tropical Diseases (NITD), Singapore, Medicinal Chemistry and Organic Chemistry.

Bryan K S Yeung - Publications - ResearchGate

www.researchgate.net/profile/Bryan_Yeung/publications
Paul W Smith, Thierry T Diagana, Bryan K S Yeung. [Show abstract] [Hide abstract] ABSTRACT: SUMMARY The number of novel antimalarial candidates ...

Bryan Yeung profiles | LinkedIn

https://www.linkedin.com/pub/dir/Bryan/Yeung
View the profiles of professionals named Bryan Yeung on LinkedIn. There are 16 professionals named Bryan Yeung, who use LinkedIn to exchange information, ...
 
 ABOUT
The Novartis Institute for Tropical Disease (NITD) is a Singapore-based tropical disease research institute created through a public-private partnership between Novartis and the Singapore Economic Development Board. Research at NITD focuses primarily on developing novel small molecule therapies for tropical infectious diseases that are endemic to the developing world, particularly dengue fever, malaria and tuberculosis.[1][2]

History and mission

NITD was founded in 2002 as a public-private partnership between Swiss-based pharmaceutical company Novartis and the Singapore Economic Development Board.[1]
NITD states its goals are "to discover novel treatments and prevention methods for major tropical diseases." Their website states they hope to have at least two drug candidates going through clinical trials in patients by the year 2012.[2]
Novartis has also stated that the NITD will seek to make treatments developed by the NITD available without profit to the poor in developing nations in which these diseases are endemic.[3]

Research

NITD is a small molecule drug discovery research institute.[1]
Research is currently focused on three main diseases:[2]
NITD's research model relies on global partnership with other research institutes.[1] In 2008, NITD announced a 5-year collaborative research effort would be conducted in cooperation with the TB Alliance to develop new medicines for tuberculosis, including drug resistant tuberculosis.[4]

Education

In addition to research, NITD is engaged in educational activities. It runs a research-based Master of Science program in fields related to infectious diseases in cooperation with National University of Singapore, University of Basel and Swiss Tropical Institute.[5]
NITD also supports training opportunities for post-graduate students and post-doctoral fellows.[2]

Fighting neglected infectious diseases

NITD Scientist
NIBR LOGO 146x50
The Novartis Institute for Tropical Diseases (NITD), one of the institutes of the Novartis Institutes for BioMedical Research (NIBR), is dedicated to finding new medicines to treat neglected, infectious diseases. As a small-molecule drug discovery research institute, it combines the drug-discovery expertise and cutting-edge technologies of Novartis to fight infectious tropical diseases, including Dengue fever, Human African Trypanomiasis and Malaria among others.
In developing countries where these diseases are endemic, Novartis will make treatments accessible to the communities that need them. NITD was set up as a public-private partnership between Novartis and the Singapore Economic Development Board (EDB) in 2002. Since then, it has grown to more than 100 researchers and supporting staff. As a major center of excellence for drug discovery, NITD will offer exceptional teaching and training opportunities for post-doctoral fellows and graduate students.
Contact NITD
Novartis Institute for Tropical Diseases Pte. Ltd.
10 Biopolis Road
#05-01 Chromos
Singapore 138670

 



EARLIER


Research Scientist II

Exelixis Inc
– (3 years 9 months) • Team member of phosphatidylinositol-3 kinase (PI3K) project that lead to a development candidate (XL765) currently in Phase Ib/2 trials.
• Design and synthesis of kinase inhibitors for use as anti-cancer agents
• Supervised an associate research scientist



 The Scripps Research Institute

The Scripps Research Institute

PostDoc, Chemistry
Synthesis and screening of a library of DNA binding agents based on analogs of distamycin A
Preparation of heterocyclic monomer building blocks for a library of DNA binding agents
Synthesis of isochrysohermidin-distamycin hybrids as new DNA binding agents

University of Illinois at Urbana-Champaign

Ph.D, Chemistry

University of Hawaii at Manoa

B.S., Chemistry




References

  1. "About NITD". Novartis AG. 2008. Retrieved 2008-12-23.
  2. "Our mission". Novartis AG. 2008. Retrieved 2008-12-23.
  3. "Commitment to Patients Earns Novartis' Dr. Daniel Vasella B'nai B'rith International's Highest Award". PharmaLive. Canon Communications Pharmaceutical Media Group. 2008-12-15. Retrieved 2008-12-23. Novartis has developed several programs aimed at enhancing affordability and access to treatment, including the Novartis Institute for Tropical Diseases, where Novartis researches novel treatments and prevention methods for neglected tropical diseases such as Dengue fever, and will make these available, without profit, to poor endemic countries.
  4. "Novartis symposium in Mozambique tackles emerging tuberculosis challenges" (media release). Basel, Switzerland: Novartis Global Communications. 2008-09-08. p. 5. Retrieved 2008-12-23. One of the core missions of the NITD is its commitment to improving access to medicines and helping reduce the overall global TB disease burden. The NITD recently announced a five-year research collaboration with the TB Alliance to develop new medicines for TB, including drug-resistant strains.
  5. "Master of Science in infectious diseases, vaccinology and drug discovery". Novartis AG. 2008. Retrieved 2008-12-23.[dead link]

External links



Patents by Inventor Bryan K. S. Yeung

Compounds and compositions for the treatment of parasitic diseases

Patent number: 8871754
Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.
Type: Grant
Filed: November 18, 2013
Issued: October 28, 2014
Assignees: IRM LLC, Novartis AG
Inventors: Arnab Kumar Chatterjee, Advait Suresh Nagle, Prasuna Paraselli, Ravinder Reddy Kondreddi, Seh Yong Leong, Pranab Kumar Mishra, Robert Joseph Moreau, Jason Thomas Roland, Wei Lin Sandra Sim, Oliver Simon, Liying Jocelyn Tan, Bryan K S Yeung, Bin Zou, Venkatataiah Bollu

Pyrazole kinase modulators and methods of use

Patent number: 8710038
Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
Type: Grant
Filed: September 15, 2005
Issued: April 29, 2014
Assignee: Exelixis, Inc.
Inventors: Tae-Gon Baik, Chris A. Buhr, Sunghoon Ma, John M. Nuss, Zerom Tesfai, Longcheng Wang, Bryan K. S. Yeung

Organic compounds

Patent number: 8399453
Abstract: The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example. Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.
Type: Grant
Filed: July 19, 2011
Issued: March 19, 2013
Assignee: Novartis AG
Inventors: Shi Hua Ang, Philipp Krastel, Seh Yong Leong, Liying Jocelyn Tan, Wei Lin Josephine Wong, Bryan K. S. Yeung, Bin Zou

Pyridopyrimidinone inhibitors of PI3K? for the treatment of cancer

Patent number: 8247408
Abstract: The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Type: Grant
Filed: October 9, 2006
Issued: August 21, 2012
Assignee: Exelixis, Inc.
Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Longcheng Wang, Bryan K. S. Yeung

ORGANIC COMPOUNDS

Application number: 20110275613
Abstract: The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example. Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.
Type: Application
Filed: July 19, 2011
Issued: November 10, 2011
Assignee: NOVARTIS AG
Inventors: Shi Hua ANG, Philipp KRASTEL, Seh Yong LEONG, Liying Jocelyn TAN, Wei Lin Josephine WONG, Bryan K.S. YEUNG, Bin ZOU

Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha

Patent number: 8044062
Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Type: Grant
Filed: October 9, 2006
Issued: October 25, 2011
Assignee: Exelixis, Inc.
Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K. S. Yeung

Pyridopyrimidinone Inhibitors of PI3Kalpha

Application number: 20110237608
Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Type: Application
Filed: June 2, 2011
Issued: September 29, 2011
Assignee: Exelixis, Inc.
Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K.S. Yeung

PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER

Application number: 20100150827
Abstract: The invention is directed to a Compound of Formula I, II, or III. The invention provides compounds that inhibit, regulate, and/or modulate PI3K that are useful in the treatment of hyperproliferatives diseases, such as cancer.
Type: Application
Filed: April 11, 2008
Issued: June 17, 2010
Assignee: Exelixis, Inc
Inventors: Chris A. Buhr, William Bajjalieh, Anagha Abhijit Joshi, Katherine Lara, Sunghoon Ma, Charles K. Marlowe, Longcheng Wang, Bryan K.S. Yeung

ORGANIC COMPOUNDS

Application number: 20090275560
Abstract: The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example, Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.
Type: Application
Filed: April 27, 2009
Issued: November 5, 2009
Assignee: NOVARTIS AG
Inventors: Shi Hua ANG, Philipp KRASTEL, Seh Yong LEONG, Liying Jocelyn TAN, Wei Lin Josephine WONG, Bryan K.S YEUNG, Bin ZOU

Pyridopyrimidinone Inhibitors of Pl3Kalpha

Application number: 20090270430
Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Type: Application
Filed: October 9, 2006
Issued: October 29, 2009
Assignee: Exelixix, Inc.
Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K.S. Yeung

Azepinoindole Derivatives As Pharmaceutical Agents

Application number: 20090203577
Abstract: The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor.
Type: Application
Filed: December 12, 2006
Issued: August 13, 2009
Assignee: EXELIXIS, INC.
Inventors: Tae-Gon Baik, Chris A. Buhr, Brett B. Busch, Diva Sze-Ming Chan, Brenton T. Flatt, Xiao-Hui Gu, Vasu Jammalamadaka, Richard George Khoury, Katherine Lara, Sunghoon Ma, Richard Martin, Raju Mohan, John M. Nuss, Jason Jevious Parks, Jason H. Wu, Bryan K. S. Yeung, Wei Xu, Tie-Lin Wang, Longcheng Wang

Pyridopyrimidinone inhibitors of pi3kalpha

Application number: 20090062274
Abstract: The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Type: Application
Filed: October 9, 2006
Issued: March 5, 2009
Assignee: Exelixis, Inc
Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Longcheng Wang, Bryan K.S. Yeung




SINGAPORE PICS
 
 
 
 
Posted by at No comments:
Labels:

One Day One Scientist honoured..........Prof Steven V Ley 28 Dec 2014









STEVE LEY


Professor Steven Ley is currently Director of Research at the Department of Chemistry, University of Cambridge following on from 21 years as the BP (1702) Professor of Chemistry and is also a Fellow of Trinity College.  Steve obtained his PhD from Loughborough University with Professor Harry Heaney and afterwards carried out postdoctoral research with Professor Leo Paquette (Ohio State University) then Professor Derek Barton (Imperial College).  He was appointed as a lecturer at Imperial College in 1975, promoted to Professor in 1983, and then to Head of Department in 1989.  In 1990 he was elected to the Royal Society (London) and was President of The Royal Society of Chemistry from 2000-2002.


Steve’s research interests are varied and span many disciplines including new synthetic methodologies, the total synthesis of natural products and the development of enabling technologies for chemical synthesis especially in the area of flow chemistry technologies.  He has published over 780 papers and has gained 50 major awards including recently the Tetrahedron Prize for Creativity in Organic Chemistry (Elsevier); Heinrich Wieland Prize (Boehringer Ingelheim, Germany); The Paracelsus Prize (Swiss Chemical Society); The Royal Medal (The Royal Society, London),  The Longstaff Prize (The Royal Society of Chemistry) and the IUPAC Thales-Nano Prize in Flow Chemistry.





Prof Steven V Ley FRS CBE FMedSci

Department of Chemistry
University of Cambridge
Lensfield Road, Cambridge
England, CB2 1EW
United Kingdom
Email: svl1000@cam.ac.uk
Tel: +44 (0)1223 336398








RESEARCH


Our research focusses on organic chemistry, the science that explores all aspects of organic compounds such as molecular structure, composition, the synthesis and properties of carbon-containing compounds and the methods and strategies that we use to achieve this.
We are committed to promoting excellence in postgraduate research through rigorous skills training and the provision of excellent laboratory facilities. We engender ambition and adventure to help our group members go on to become future pioneers and leaders in their own right.
The heart of our research interests lies in the discovery and development of new chemical methodologies, in the broadest sense. A main focus for us is tackling the challenges facing chemical manufacturing in the future and addressing strategic needs for more sustainable processes in chemical synthesis.

..............
Steven Victor Ley FRS is the BP Professor of Organic Chemistry at the University of Cambridge, and is a Fellow of Trinity College. He was President of the Royal Society of Chemistry (2000–2002) and was made a CBE in January 2002. In 2011, he was included by The Times in the list of the “100 most important people in British science”.[1]
His main research field is the total synthesis of biomolecules. His group has published extensively on this topic, and has completed the synthesis of more than 140 natural target compounds, with notable examples including indanamycin, routiennocin, avermectin B1a, okadaic acid, spongistatin, thapsigargin, epothilone A, antascomicin B, bengazole A andrapamycin. His total synthesis of azadirachtin, completed in 2007, is widely regarded as one of the major landmarks in total synthesis. In the course of this work, he has also made substantial advances in many areas of organic chemistry, including the development of new catalysts, protecting groups and reagents. He is one of the inventors of TPAP, a widely employed oxidizing reagent. He has also pioneered the use of immobilized reagents and flow techniques in multi-step organic synthesis. This work now incorporates flow chemistry for multistep organic synthesis applications.

Honours and Awards[edit]

Steve Ley's work of almost 800 papers has been recognised by about 40 major prizes and awards, the most recent of which are:






798. The rapid synthesis of oxazolines and their heterogeneous oxidation to oxazoles under flow conditions, S. Glockner, D.N. Tran, R.J. Ingham, S. Fenner, Z.E. Wilson, C. Battilocchio, S.V. Ley Org. Biomol. Chem., 2015, 13, 207
GA
797. Process intensification for the continuous flow hydrogenation of ethyl nicotinate, T. Ouchi, C. Battilocchio, J.M. Hawkins, S.V. LeyOrg. Process Res. Dev., 2014, 18, 1560-1566
op500208j copy
796.  Reconfiguration of a continuous flow platform for extended operation: application to a cryogenic fluorine-directed ortho-lithiation reaction, J.A. Newby, D.W. Blaylock, P.M. Witt, R.M. Turner, P.L. Heider, B.H. Harji, D.L. Browne, S.V. Ley, Org. Process Res. Dev., 2014, 18, 1221-1228
op-2014-00221s_0013
795. Design and application of a low-temperature continuous flow chemistry platform, J.A. Newby, D.W. Blaylock, P.M. Witt, J.C. Pastre, M.K. Zacharova, S.V. Ley, D. L. Browne, Org. Process Res. Dev.,2014, 18, 1211-1220
op-2014-00213j_0006
tfigure6793. Regioselective preparation of saturated spirocyclic ring-expanded fused pyrazoles R.R. Merchant, D.M.Allwood, D.C.Blakemore, S.V.Ley, J. Org. Chem., 2014, 880-8811
jo-2014-01624t_0012
792. Flow chemistry meets advanced functional materials R.M. Myers, D.E. Fitzpatrick, R.M. Turner, S.V. Ley, Chem. Eur. J.  2014, 20, 12348-12366
792. Chem. Eur. J., 2014, 20, 12348-12366
791. Expedient preparation of nazlinine and a small library of indole alkaloids using flow electrochemistry as an enabling technology M.A. Kabeshov, B. Musio, P.R.D. Murray, D.L. Browne, S.V.Ley, Org. Lett.  2014, 16, 4618-4621
ol502201d
790. Highly regioselective lithiation of pyridines bearing an oxetane unit by n-butyllithium G. Rouquet, D.C. Blakemore, S.V. Ley, Chem. Comm. 2014, 50, 8908-8911
GA
789. Synthesis of riboflavines, quinoxalinones and benzodiazepines through chemoselective flow based hydrogenations, M. Baumann, I.R. Baxendale, C.H. Hornung, S.V. Ley, M.V. Rojo, K.A. Roper, Molecules 2014, 19, 9736-9759
molecules-19-09736-ag



External links

References

  1.  [1]
  2.  [2]
  3.  Tetrahedron Prize for Creativity in Organic Chemistry
  4. Jump up^ "Director of the Department of Chemistry, University of Cambridge, UK - Heinrich Wieland Prize 2009 for outstanding achievements in the synthesis of key natural products".http://www.heinrich-wieland-prize.de. Retrieved 7 October 2014.


CAMBRIDGE





























DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter     
Join me on google plus Googleplus

 amcrasto@gmail.com


Posted by at No comments:
Labels: , , ,
Subscribe to: Posts (Atom)